HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sheng, H. Articles by Beauchamp, R. D. Search for Related Content PubMed PubMed Citation Articles by Sheng, H. Articles by Beauchamp, R. D. Social Bookmarking                      What's this?

J Biol Chem, Vol. 275, Issue 9, 6628-6635, March 3, 2000

Transforming Growth Factor-1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA^*

Hongmiao Sheng^§, Jinyi Shao^¶, Dan A. Dixon, Christopher S. Williams^¶, Stephen M. Prescott, Raymond N. DuBois^¶**, and R. Daniel Beauchamp^§**

From the Departments of  Surgery, ^¶ Medicine, and ^** Cell Biology, The Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 and  Eccles Program in Human Molecular Biology and Genetics, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Oncogenic ras induces the expression of cyclooxygenase-2 (COX-2) in a variety of cells. Here we investigated the role of transforming growth factor- (TGF-) in the Ras-mediated induction of COX-2 in intestinal epithelial cells (RIE-1). RIE-1 cells were transfected with an inducible Ha-Ras^Val12 cDNA and are referred as RIE-iRas cells. the addition of 5 mM isopropyl-1-thio--D-galactopyranoside (IPTG) induced the expression of Ha-Ras^Val12, closely followed by an increase in the expression of COX-2. Neutralizing anti-TGF- antibody partially blocked the Ras-induced increase in COX-2. Combined treatment with IPTG and TGF-1 resulted in a 20-50-fold increase in the levels of COX-2 mRNA. The t_1/2 of COX-2 mRNA was increased from 13 to 24 min by Ha-Ras induction alone. The addition of TGF-1 further stabilized the COX-2 mRNA (t_1/2 > 50 min). Stable transfection of a luciferase reporter construct containing the COX-2 3'-untranslated region (3'-UTR) revealed that TGF-1 treatment and Ras induction each stabilized the COX-2 3'-UTR. Combined treatment with IPTG and TGF-1 synergistically increased the luciferase activity. Furthermore, a conserved AU-rich region located in the proximal COX-2 3'-UTR is required for maximal stabilization of COX-2 3'-UTR by Ras or TGF-1 and is necessary for the synergistic stabilization of COX-2 3'-UTR by oncogenic Ras and TGF-1.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Although increased expression of COX-2¹ in human and rodent intestinal tumors has been widely observed (1-4), the mechanisms that regulate the expression of COX-2 in colonic tumors are not completely understood. COX-2 expression is induced by cytokines, growth factors, and tumor promoters (reviewed in Ref. 5). Up-regulation of COX-2 is a downstream effect of Ras-mediated transformation in intestinal epithelial cells (RIE-1) (6), fibroblasts (7), mammary epithelial cells (8), and non-small cell lung cancer cells (9). The mechanisms underlying the regulation of COX-2 expression are complex. Previously, it was reported that COX-2 expression was regulated at the transcriptional level by activated Ha-ras in mammary cells (8, 10) and by oncogene v-src (11) and growth factors (12) in NIH 3T3 cells. Interleukin-1 induced rapid but transient activation of COX-2 transcription and also prolonged the half-life of the COX-2 mRNA (13). Post-transcriptional regulation of cytokine-induced cyclooxygenase-2 transcript isoforms by dexamethasone has also been reported (14). We have found that the induction of COX-2 in conditionally Ha-Ras^Val12-transformed Rat-1 cells occurs via a modest increase (~50%) in COX-2 transcription and a 3-fold increase in the half-life of COX-2 mRNA (7).

The TGF-s are 25-kDa homodimeric polypeptides belonging to a superfamily of growth regulatory molecules. TGF- has previously been characterized as a potent growth inhibitor for cultured rat intestinal crypt cells (15-18). Through the activation of specific receptors, the TGF- ligands activate the Smad signal transduction pathway, which appears to serve an important tumor suppressor function (19-22). However, there is mounting evidence that TGF- may enhance malignant transformation and tumor progression for several different epithelial tumors under certain circumstances (23-29). One of the remarkable effects of TGF- on intestinal epithelial cells and other cell types is the induction or augmentation of COX-2 expression (4, 29-34). Expression of either activated Ras or Src proteins activates transcription of the TGF-1 gene (35, 36). Furthermore, TGF- collaborates with oncogenic Ras in the transformation of mammary epithelial cells (28). Based upon the observations that COX-2 was overexpressed in 85-90% of human colon cancers (1) and that TGF- was abnormally expressed in over 90% of human colon cancers (37), we hypothesized that TGF- may play a role in the regulation of COX-2 expression during the adenoma to carcinoma sequence of events that are involved in the neoplastic transformation of colonic epithelial cells (4).

This study describes the observation that TGF- synergistically enhances the expression of COX-2 in conditionally Ha-Ras-transformed intestinal epithelial cells. We have also evaluated the mechanisms by which Ras and TGF- mediate the induction of COX-2. TGF--neutralizing antibody partially inhibits the increased expression of COX-2 after induction of Ha-Ras, suggesting an important autocrine effect of Ras-induced TGF-1 expression. Both Ha-Ras^Val12 and TGF-1-mediated induction of COX-2 involve stabilization of COX-2 mRNA, and the combined effects of Ha-Ras^Val12 and TGF- treatment cause a synergistic increase in COX-2 mRNA by prolonging the half-life of the mRNA. Using chimeric reporter constructs containing the COX-2 3'-untranslated region (3'-UTR) linked to the luciferase reporter gene, we provide the evidence that this region contains the cis-acting elements necessary to confer both Ha-Ras and TGF- responsiveness.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Cell Culture-- RIE-iRas cell line with an inducible activated Ha-Ras^Val12 cDNA was generated by using LacSwitch eukaryotic expression system (Stratagene, La Jolla, CA) and was maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 400 µg/ml G418 (Life Technologies, Inc.), and 150 µg/ml hygromycin B (Calbiochem). The Ha-Ras^Val12 cDNA is under the transcriptional control of the Lac operon in rat intestinal epithelial (RIE-1) cells. Isopropyl-1-thio--D-galactopyranoside (IPTG; Life Technologies, Inc.) at a concentration of 5 mM was used to induce the expression of mutated Ha-Ras. Anti-TGF- antibody (R&D Systems, Inc. Minneapolis MN) was used to block the endogenous TGF- activity.

RNA Extraction and Northern Blot Analysis-- The extraction of total cellular RNA was performed as described previously (7). RNA samples (20 µg/lane) were separated on formaldehyde-agarose gels and blotted onto nitrocellulose membranes. The blots were hybridized with cDNA probes labeled with [-³²P]dCTP by random primer extension (Stratagene). After hybridization and washes, the blots were subjected to autoradiography. 18 S rRNA signals were used as controls to determine integrity of RNA and equality of the loading. For determination of mRNA stability, RIE-iRas cells were treated with IPTG, TGF-1, or both IPTG and TGF-1 for 24 h, then the transcription was stopped by the addition of 100 µM DRB (5,6-dichlorobenzimidazole riboside; Sigma). The RNA samples were isolated at 0, 10, 20, 30, 40, and 50 min following the DRB treatment and analyzed for mRNA levels by Northern blotting.

Immunoblot Analysis-- Immunoblot analysis was performed as described previously (38). Briefly, the cells were lysed for 30 min in radio immunoprecipitation assay buffer (1× phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 1 mM sodium orthovanadate), then clarified cell lysates were denatured and fractionated by SDS-polyacrylamide gel electrophoresis. After electrophoresis, the proteins were transferred to nitrocellulose membrane. The filters were then probed with the indicated antibodies, developed by the enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech), and exposed to X-AR5 film (Eastman Kodak Co.). Quantitation was by densitometry. The anti-COX-2 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-pan Ras antibody was purchased from Calbiochem.

Transfection of Reporter Constructs-- Reporter construct phPES2(327/+59) containing the 5'-flanking region of the human COX-2 gene (nucleotides 327 to +59) was a kind gift of Dr. H. Inoue (National Cardiovascular Center Research Institute, Osaka, Japan) and described previously (39). phPES2(327/+59) was co-transfected with pcDNA3/zeo into RIE-iRas cells. Transfected cells were selected by neomycin (600 µg/ml), hygromycin (150 µg/ml), and zeocin (250 µg/ml). Pooled clones were used for determine the luciferase activity.

The construction of reporter expression vectors pLuc+3'-UTR, pLuc+3'-UTRARE, and pLuc+ARE was described elsewhere.² Briefly, a reporter vector, pLuc, was generated by inserting the luciferase cDNA into pcDNA3/zeo (Invitrogene, Carlsbad, CA). The addition of the COX-2 3'-UTR (1451 bp) was accomplished by polymerase chain reaction amplification of the COX-2 3'-UTR using XbaI-tailed primers and inserting them adjacent to the luciferase coding region to yield pLuc+3'-UTR. pLuc+3'-UTRARE was generated by digesting pLuc+3'-UTR with ApaI and ScaI to release a 1036-bp region of the COX-2 3'-UTR, and this 3'-UTR region was cloned into the ApaI and filled-in XbaI sites of pLuc. For pLuc+ARE, pLuc+3'-UTR was digested with PmeI and ScaI to generate a 1818-bp Luc+ARE fragment that was inserted into pcDNA3/zeo vector. RIE-iRas cells were transfected with pLuc (RIE-iRas/luc), pLuc+3'-UTR (RIE-iRas/Luc+3'-UTR), pLuc+3'-UTRARE (RIE-iRas/Luc+3'-UTRARE), or pLuc+ARE (RIE-iRas/Luc+ARE). The stable transfected clones were selected with neomycin (600 µg/ml), hygromycin (150 µg/ml), and zeocin (250 µg/ml). For the luciferase activity assay, cells were treated for the indicated hours and lysed with passive lysis buffer (Promega, Madison WI). Twenty µl of lysate was used for the firefly luciferase reading by using a luciferase reporter assay system (Promega) and a model TD-20/20 luminometer. Firefly luciferase values were standardized to the protein contents and presented as mean ± S.E. of assays performed in triplicate.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Ha-Ras-mediated Transformation and Induction of COX-2-- We previously reported that COX-2 expression is significantly increased in a rat intestinal epithelial cell line stably transformed by Ha-Ras (6) and conditional expression of Ha-Ras rapidly induced the expression of COX-2 in rat fibroblasts (7). To determine whether COX-2 is an early target of oncogenic Ha-Ras in RIE cells, we have introduced the inducible Ha-Ras^Val12 cDNA vectors into the RIE-1 cells (RIE-iRas). Noninduced RIE-iRas cells displayed the same nontransformed morphology as the parental RIE-1 cells. Morphological transformation of the RIE-iRas cells was observed between 24-48 h after IPTG treatment. During this interval, cell-cell contact inhibition was lost. The cells acquired a spindly appearance and grew in overlapping clusters (Fig. 1A). The morphological transformation of RIE-iRas cells could be completely reversed upon withdrawal of IPTG for 72 h (72 h). As shown in Fig. 1B, the addition of IPTG into the culture medium induced activated Ha-Ras protein by 4 h. Thereafter, the level of Ras protein was continuously elevated for the duration of IPTG treatment. COX-2 was expressed at very low levels in RIE-iRas cells before IPTG treatment. The elevation of COX-2 protein was detected by 8 h after the addition of IPTG. The induction of COX-2 temporally coincided with the induction of Ha-Ras protein.

View larger version (71K): [in this window] [in a new window]   Fig. 1.   Ras-mediated transformation and induction of COX-2. A, morphological transformation of RIE-iRas cells. RIE-iRas cells were grown on 60-mm tissue culture dishes. The cells were treated with 5 mM IPTG for 0, 24, or 72 h, then IPTG was removed for 72 h (72 h). The pictures were taken by using an inverted microscope (original magnification, ×100). B, induction of Ha-Ras and COX-2. RIE-iRas cells were treated with IPTG and lysed in radio immunoprecipitation assay buffer (1× phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 1 mM sodium orthovanadate) at the indicated time points. 50 µg of each cell lysates were fractionated by SDS-polyacrylamide gel electrophoresis. After electrophoresis, the proteins were transferred to nitrocellulose membranes. The filters were blotted with the indicated antibodies and developed by the ECL chemiluminescence system.

We next investigated whether Ras-induced expression of COX-2 involves signaling through TGF-. Northern analysis revealed that induction of Ras significantly increased the levels of TGF-1 mRNA (Fig. 2A). In the absence of Ras induction, the addition of exogenous TGF-1 transiently increased the levels of COX-2 in RIE-iRas cells, with a peak between 12-24 h following TGF- treatment (Fig. 2B). To determine whether endogenous TGF- mediates a component of the Ras-induced COX-2 expression, TGF--neutralizing antibody was added before the IPTG treatment. Indeed, induction of COX-2 by activated Ha-Ras was partially blocked by TGF--neutralizing antibody (Fig. 2C), implying a functional autocrine role for TGF- in Ras-mediated induction of COX-2.

View larger version (21K): [in this window] [in a new window]   Fig. 2.   The role of TGF- in Ras induction of COX-2. A, Northern analyses of TGF-1 in RIE-iRas cells. Cells were treated with 5 mM IPTG for the indicated hours. Total RNA was isolated for detection of TGF-1 mRNA expression. B, TGF-1 induction of COX-2. RIE-iRas cells were treated with 3 ng/ml TGF-1 for the indicated hours. Cell lysates were collected and subjected to Western analyses for COX-2. C, anti-TGF- antibody inhibition of Ras-induced COX-2. RIE-iRas cells were treated with IPTG and with or without 10 µg/ml anti-TGF- antibody. Cell lysates were collected at the indicated time points and the levels of COX-2 were analyzed by Western analysis.

TGF- Enhances Ras-mediated Induction of COX-2-- Although TGF- expression is normally restricted to the lumenal one-third of the intestinal epithelium (16, 40), the interstitial cells may produce large amounts of paracrine TGF-. It was of interest to determine whether there was a cooperative effect of exogenous TGF-1 and oncogenic Ras on the expression of COX-2. The RIE-iRas cells were treated with 3 ng/ml TGF-1 without IPTG, and the levels of COX-2 mRNA were analyzed by Northern blotting. As shown in Fig. 3A, in the absence of Ras induction, treatment with TGF-1 increased the level of COX-2 mRNA, which reached a peak (3.5-fold) by 8 h after the treatment. Induction of Ras by IPTG treatment increased the levels of COX-2 mRNA by 8 h, and the levels remained at an elevated plateau between 12-72 h. Interestingly, combined treatment with TGF-1 and IPTG resulted in a marked induction of COX-2. The levels of COX-2 mRNA were synergistically elevated by the combination of TGF-1 and Ras by 24 h after the combined treatment. A 20-50-fold increase in the levels of COX-2 mRNA was observed between 24-72 h. Western analysis further confirmed that the increased levels of COX-2 mRNA level also reflected an increase in the level of COX-2 protein (Fig. 3B).

View larger version (41K): [in this window] [in a new window]   Fig. 3.   TGF-1 enhancement of Ras induction of COX-2. A, Northern analysis of COX-2 in RIE-iRas cells. Cells were treated with 3 ng/ml TGF-1 or 5 mM IPTG or both TGF-1 and IPTG for the indicated hours. Total RNA was isolated for detection of the levels of COX-2 mRNA. B, Western analysis of COX-2 in RIE-iRas cells. Cells were treated with 5 mM IPTG or IPTG plus 3 ng/ml TGF-1 for the indicated hours. Cellular protein was isolated for detection of the levels of COX-2 protein.

Stabilization of Ras-induced COX-2 mRNA by TGF- Treatment-- We have previously reported that induction of Ha-Ras stabilizes COX-2 mRNA in Rat-1 fibroblasts (7). To determine the mechanism of synergistic induction of COX-2 that results from oncogenic Ras and TGF-1, we examined the stability of COX-2 mRNA in RIE-iRas cells after TGF-1 and IPTG treatment. RIE-iRas cells were treated with IPTG, TGF-1, or both IPTG and TGF-1 for 24 h, then transcription was stopped by the addition of 100 µM DRB. The RNA samples were isolated at 0, 10, 20, 30, 40, and 50 min following the DRB treatment and analyzed for mRNA levels by Northern blotting. As demonstrated in Fig. 4, A and B, COX-2 mRNA was rapidly degraded in noninduced RIE-iRas cells (t_1/2 ~ 13 min). Individually, either TGF-1 or IPTG treatment increased the stability of COX-2 mRNA to a similar extent (t_1/2 ~ 24-30 min). The COX-2 mRNA from the RIE-iRas cells after combined TGF-1 and IPTG treatment was extremely stable, and the t_1/2 was greater than 50 min.

View larger version (40K): [in this window] [in a new window]   Fig. 4.   Degradation of COX-2 mRNA. A, RIE-iRas cells were treated with vehicle, IPTG, TGF-1, or both IPTG and TGF-1 for 24 h. Then transcription was stopped by the addition of 100 µM DRB. The RNA samples were isolated at the indicated time points following DRB treatment for detection of the levels of COX-2 mRNA. B, degradation curves of COX-2 mRNA. The results from A were densitometrically analyzed by using the NIH image program and normalized by 18 S. The half-life (t1/2) of the mRNA is indicated on the right side of the curve. CTR, control.

To further study transcriptional and post-transcriptional regulation of COX-2 in RIE-iRas cells, we transfected the luciferase reporter gene linked with either COX-2 promoter region or 3'-UTR into RIE-iRas cells. The 5'-flanking region of the human COX-2 gene (nucleotides 327 to +59) includes the nuclear factor responsible for Interleukin-6 expression (NF-IL6) site and the cyclic AMP response element (CRE) (39). This reporter gene exhibited promoter activity that was modestly increased by induction of oncogenic Ras or by the addition of exogenous epidermal growth factor (EGF) (Fig. 5A). Treatment with TGF-1 for 6 and 24 h did not alter the activity of this promoter region.

View larger version (33K): [in this window] [in a new window]   Fig. 5.   Luciferase activity assay. A, transfection of reporter vector under the transcriptional control of COX-2 promoter (327/+59). RIE-iRas cells were co-transfected with phPES2(327/+59) containing the 5'-flanking region of the human COX-2 gene (nucleotides 327 to +59) and pcDNA3/zeo. Pooled stable transfectants were selected by the addition of 300 µg/ml zeocin. Cells were plated in 24-well plates and treated with or without 5 mM IPTG for 24 h. Cells were washed twice with phosphate-buffered saline and lysed with passive lysis buffer. 20 µl of lysate was used for the firefly luciferase readings. Plotted is the mean ± S.E. B, stable transfection of reporter constructs linked with COX-2 3'-UTR. RIE-iRas cells were transfected with pcDNA3/Luc or pcDNA3/Luc+3'-UTR, and stable transfectants were selected by addition of 300 µg/ml zeocin in cultural medium. For the luciferase assay, established clones (15 RIE-iRas/luc and 31 RIE-iRas/Luc+3'-UTR clones) were plated in 24-well plates and treated with or without 5 mM IPTG for 24 h. Cells were washed twice with phosphate-buffered saline and lysed with passive lysis buffer. 20 µl of lysate was used for the firefly luciferase readings. Plotted is the mean ± S.E. C, levels of luciferase mRNA in RIE-iRas/Luc+3'-UTR cells. Cells were treated with IPTG, and total RNA was collected at the indicated time points. The Northern blot was probed with [32P]dCTP-labeled luciferase cDNA. The levels of 18 S rRNA are shown as loading controls. D, stabilization of COX-2 3'-UTR by Ras and TGF-1 treatment. Representative clones of RIE-iRas/luc or RIE-iRas/Luc+3'-UTR cells were treated with IPTG, TGF-1, or both IPTG and TGF-1 for the indicated hours. Luciferase activity was measured and plotted as mean ± S.E.

We next engineered the RIE-iRas cells to express the cytomegalovirus promoter-driven luciferase reporter gene alone (RIE-Ras/luc) or linked with 1.5 kilobases of COX-2 3'-UTR (RIE-iRas/luc+3'-UTR). Stably transfected clones were selected and analyzed. Treatment with IPTG for 24 h increased the luciferase activity by 100% in RIE-iRas/luc+3'-UTR cells but did not alter the luciferase activity in RIE-iRas/luc control cells (Fig. 5B). These results suggested that induction of Ras stabilized luciferase mRNA via the linked COX-2 3'-UTR and not through a transcriptional induction of the luciferase gene alone. Northern blot analysis confirmed that the increased luciferase activity resulted from an increase in the levels of luciferase mRNA (Fig. 5C). The level of luciferase mRNA was clearly elevated by 8 h after the induction of Ha-Ras. A 2-3-fold increase in the level of luciferase mRNA was observed between 24-48 h after Ha-Ras^Val12 was induced by the addition of IPTG (Fig. 5C).

There was no significant induction of luciferase activity in control RIE-iRas/luc cells that were treated with IPTG, TGF-1, or both IPTG and TGF-1 for 6, 24, and 72 h (Fig. 5D). However, the luciferase activity in RIE-iRas/luc+3'-UTR cells was induced by either IPTG or TGF-1 treatment. The luciferase activity was additively increased by 24 h after combined treatment with TGF-1 and IPTG. A synergistic increase in luciferase activity was observed by 72 h after the RIE-iRas/luc+3'-UTR cells were treated with both TGF-1 and IPTG. These results are consistent with the findings of Northern analysis described in Fig. 3A.

The 3'-untranslated region of the COX-2 transcript is extremely AU-rich and contains 14 copies of the Shaw-Kamens sequence (AUUUA), otherwise known as AU-rich elements (AREs) (41). To determine whether the stabilization of COX-2 mRNA by oncogenic Ras and TGF-1 treatment was dependent upon highly conserved AU-rich elements located in the proximal COX-2 3'-UTR (14), we constructed two additional reporter vectors. The pLuc+3'-UTRARE construct was derived from pLuc+3'-UTR by removal of a fragment of 415 bp of nucleotide including 8 conserved AU-rich elements from the proximal COX-2 3'-UTR. For the pLuc+ARE, the 415 bp of conserved AU-rich fragment was linked to the downstream of luciferase cDNA in pLuc vector (see "Experimental Procedures"). RIE-iRas cells were transfected with either pLuc+3'-UTRARE or pLuc+ARE. Stably transfected clones were selected by the treatment with zeocin, pooled, and referred to as RIE-iRas/Luc+3'-UTRARE or RIE-iRas/Luc+ARE.

IPTG treatment (Ha-Ras induction) of the RIE-iRas/Luc+3'-UTRARE cells resulted in a 44% increase in luciferase activity after 24 h (Fig. 6A) and a 3-fold increase after 72 h (Fig. 6B). Treatment of the RIE-iRas/Luc+3'-UTRARE cells with TGF-1 alone altered luciferase activity by no more than 27%, and the combination of TGF-1 and IPTG did not increase the levels over that observed with IPTG alone (Fig. 6, A and B). In contrast, in the RIE-iRas/Luc+ARE cells, IPTG treatment increased luciferase activity 5.4-fold by 24 h (Fig. 6A) and 7.2-fold by 72 h (Fig. 6B). TGF-1 treatment of the RIE-iRas/Luc+ARE cells increased luciferase activity 4.7-fold by 24 h (Fig. 6A) and 2.9-fold by 72 h (Fig. 6B) after treatment. Treatment of RIE-iRas/Luc+ARE cells with the combination of IPTG and TGF-1 increased the luciferase activity 15.7-fold by 24 h (Fig. 6A) and 23-fold by 72 h (Fig. 6B). Thus, the conserved 415-bp ARE region of the COX-2 3'-UTR appears to be necessary for the synergistic increase in expression caused by the combination of activated Ras and TGF-1.

View larger version (20K): [in this window] [in a new window]   Fig. 6.   The role of AREs in stability of COX-2 mRNA. A, stable transfection with pLuc+3'-UTRARE and pLuc+ARE. A conserved 415-bp AU-rich region including 8 AUUUA elements was removed from the proximal COX-2 3'-UTR. The mutated COX-2 3'-UTR was inserted into pcDNA3/Luc reporter vector (pLuc+3'-UTRAR). RIE-iRas cells were stably transfected with pLuc+3'-UTRARE (RIE-iRas/Luc+3'-UTRARE) and were treated with IPTG or TGF-1 or both IPTG and TGF-1 for 24 h (ARE). Luciferase activity was measured and plotted as mean ± S.E. The conserved 415-bp AU-rich region including 8 AUUUA elements was linked to the downstream luciferase gene in pLuc vector (pLuc+ARE). RIE-iRas cells were transfected with pLuc+ARE. Stable transfected cells were treated with IPTG or TGF-1 or both IPTG and TGF-1 for 24 h (+ARE). Luciferase activity was measured and plotted as mean ± S.E. B, RIE-iRas/Luc+3'-UTRARE cells (ARE) and RIE-iRas/Luc+ARE (+ARE) cells were treated with IPTG or TGF-1 or both IPTG and TGF-1 for 72 h. Luciferase activity was measured and plotted as mean ± S.E.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Numerous studies have suggested that cyclooxygenase activity and prostaglandin synthesis may be involved in intestinal carcinogenesis. COX-2 expression is increased in human colorectal adenocarcinomas when compared with normal adjacent colonic mucosa (1-3). Furthermore there is mounting evidence that COX-2 expression in colorectal cancer cells provides a growth and survival advantage (42), increases tumor cell invasiveness (43), and enhances tumor angiogenesis (44). The importance of cyclooxygenase function in colorectal tumorigenesis is further supported by the observations that chronic ingestion of nonsteroidal anti-inflammatory drugs is associated with a reduced incidence of colorectal cancer in humans (45). Nonsteroidal anti-inflammatory drugs can also significantly inhibit colorectal tumorigenesis in animal models (46, 47). Selective inhibition of COX-2 activity is particularly effective in this preventive effect (48, 49). The present study demonstrates that exposure of Ras-transformed cells to TGF- results in a synergistic increase in COX-2 expression.

We had previously observed that TGF-1 transiently induced the expression of COX-2 in nontransformed RIE cells (34). TGF- expression is increased in a wide variety of cancers (including colon cancer) relative to adjacent normal tissues (50). We previously observed that chronic TGF-1 treatment resulted in both morphologic transformation and constitutive overexpression of COX-2 in cultured rat intestinal epithelial cells (29). We have also observed coordinate high level expression of both COX-2 and TGF-1 in colorectal adenomas and carcinomas (4). Transformation of cells with dominant oncogenes (e.g. Ha-ras or v-src) results in transcriptional activation of the TGF-1 gene (35, 36). Activation of the Ki-ras oncogene occurs frequently in colorectal cancers (51). Increased expression of COX-2 after Ras transformation has also been reported in both epithelial cells (8) and in fibroblasts (7). Our observation that TGF--neutralizing antibody partially inhibited the increase in COX-2 induced by activated Ha-Ras suggests that TGF- contributes to the increase in COX-2 in an autocrine manner. In cooperation with oncogenic Ras, the addition of exogenous TGF-1 caused a persistent synergistic induction of COX-2 at both the mRNA and protein levels. Thus, autocrine and paracrine TGF- may contribute to the overexpression of COX-2 that occurs in transformed intestinal epithelial cells.

Thus far, most studies of the COX-2 regulation have focused on the transcriptional mechanism of induction (8, 10-12, 52-54). An exception was the observation of post-transcriptional destabilization of cytokine-induced cyclooxygenase-2 transcript isoforms by dexamethasone as reported by Ristimaki et al. (13, 14). Our previous studies demonstrated that the induction of COX-2 in Rat-1 cells conditionally transformed by Ha-Ras^Val12 occurred due to the combined effects of a modest (~50%) increase in transcription and a more significant (3-fold) increase in the stability of COX-2 mRNA (7). In the present study, we confirmed that induction of Ha-Ras modestly increased the promoter activity of the COX-2 5'-flanking region (327/+59), whereas TGF- did not activate the COX-2 promoter. In contrast, either Ha-Ras^Val12 induction or TGF-1 treatment individually increased the half-life of COX-2 mRNA, whereas the combination of Ras induction and TGF-1 treatment markedly increased the half-life of COX-2 mRNA. Both the induction of the Ras and TGF- treatment increased the expression of luciferase, an effect that was mediated by the COX-2 3'-UTR contained in the chimeric Luc-COX-2 3'-UTR vector. Combined Ras and TGF-1 effects resulted in synergistic increase in the expression of Luc-COX-2 3'-UTR. We conclude that this inducible increase in expression of Luc-COX-2 3'-UTR was due to an increase in the stability of the mRNA. Neither Ras induction nor TGF-1 treatment induced luciferase activity in control cells that were transfected with the cytomegalovirus-driven luciferase controls containing no COX-2 3'-UTR. Our finding of increased steady-state levels of luciferase mRNA in the absence of increased transcription leads us to conclude that the increased luciferase activity reflects an increase in mRNA stability that has been conferred by the COX-2 3'-UTR. While we have confirmed that a significant portion of the increase in COX-2 expression after Ras activation and exposure to TGF- is due to increased mRNA stability, we have not excluded the possibility that increased translational efficiency may also contribute the increased expression of COX-2.

The 3'-untranslated region of the COX-2 transcript is extremely AU-rich, and contains 14 copies of the Shaw-Kamens sequence (AUUUA) otherwise known as AU rich elements (AREs) (41, 55, 56). This motif is present in many immediate early genes and is thought to be involved in the regulation of mRNA degradation (57, 58). In our study, removal of 415 bp of nucleotide including first 8 AREs from proximal COX-2 3'-UTR significantly reduced and delayed the Ras induced stabilization of COX-2 3'-UTR. TGF-1-induced stabilization of COX-2 3'-UTR was almost completely abolished by removal of this AU-rich region. The synergistic increase in Luc-COX-2 3'-UTR expression clearly required the presence of this AU-rich region. In addition, linkage of the eight ARE clusters to a luciferase reporter gene resulted in an enhanced stabilization of luciferase by TGF-1 and Ras. Synergistic induction of luciferase activity by Ras and TGF-1 indicates the important role of this AU-rich region in stabilization of COX-2 mRNA. Chen et al. (58) recently report that interleukin-2 mRNA contains at least two cis elements that mediate its stabilization in response to different signals. A cis element encompassing the 5'-UTR and the beginning of the coding region mediates the stabilization that resulted from activation of c-Jun amino-terminal kinase (JNK), whereas other signals may modulate the stability of interleukin-2 mRNA through the 3'-UTR. These findings suggest that multiple elements within interleukin-2 mRNA modulate its stability in a combinatorial manner. The present studies do not exclude the possibility of cis elements in addition to those in the 3'-UTR that may contribute to COX-2 mRNA stability.

There are several lines of evidence that neoplastic transformation results in abrogation of TGF--mediated growth inhibitory and tumor suppressive effects. For example, the loss of growth inhibitory responsiveness after Ras transformation is associated with a decrease in the levels of type II TGF- receptor (17, 59) and inhibitory phosphorylation of the TGF- signaling proteins Smad2 and Smad3(60). On the other hand, TGF- may actually promote malignant transformation and tumor progression by several different mechanisms. TGF- may suppress tumor immunosurveillance (23). TGF- exhibits growth inhibitory effects on moderate to well differentiated primary colon carcinomas but stimulates the proliferation and invasion of poorly differentiated and metastatic colonic carcinomas (61, 62). TGF-1 can induce estrogen-independent tumorigenicity of human breast cancer cells (63). TGF- treatment can also substitute for wounding as a promoter of fibrosarcomas in chickens infected with the Rous sarcoma virus (24, 25). There is mounting evidence that autocrine TGF- expression by tumor cells plays a major role in the epithelial-to-fibroblastoid conversion in mammary cells (28) and in keratinocytes (27, 64) that accompanies malignant transformation. TGF-1 overexpression in transgenic mouse keratinocytes tends to inhibit the appearance of carcinogen- induced benign skin tumors, but for more advanced lesions, TGF-1 overexpression enhanced progression toward the malignant spindle-cell phenotype (27). The TGF--induced epithelial-to-mesenchymal transition in Ha-Ras-transformed mammary epithelial cells involves disrupted cell-cell adhesion and the loss of epithelial cell polarity in addition to causing the cells to become more spindle-shaped and invasive (28). Furthermore, chronic exposure to high concentrations of TGF-1 promotes the spontaneous neoplastic transformation of cultured rat liver epithelial cells (26).

We have recently reported that chronic exposure of rat intestinal epithelial (RIE-1) cells resulted in neoplastic transformation as defined by loss of growth inhibitory response to TGF-, loss of contact inhibition, acquisition of a fibroblast-like spindle cell morphology, anchorage-independent growth, and tumorigenicity in athymic mice (29). These TGF--resistant RIE-1 cells (called RIE-TR) also exhibited markedly increased expression of COX-2 and TGF-1. Taken together, these observations in experimental tumor models suggest that tumor cells have not only lost the growth-inhibitory response to TGF-, but that TGF- then promotes the malignant phenotype in transformed cells. TGF- induction of COX-2 in cancer cells may contribute to this aggressive phenotype. TGF- expression in human cancers may also have detrimental significance. In human colorectal cancers, high level expression of TGF-1 in the primary tumor is an independent predictor of risk (18-fold) for recurrence (65) and advanced stage with reduced survival in colorectal cancer patients (66).

Our present findings demonstrate that TGF-1 synergistically increases Ras-induced expression of COX-2, largely via an increase in the stability of COX-2 mRNA. The synergistic increase in COX-2 mRNA stability requires the presence of the conserved ARE region found within the proximal 500 bp of the 3'-UTR. These results point to a novel mechanism by which TGF- and activated Ras collaborate to increase the expression of an important effector of tumor progression. Further studies to determine the mechanism of this induced stabilization of the COX-2 mRNA in transformed cells may yield important insights into the process of tumor progression.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grants DK-52334 and CA-69457 (to R. D. B.), DK-47297 and ES-00267 (to R. N. D.), P01 CA77839 and CA 68485 (Vanderbilt Cancer Center), (to R. D. B. and R. N. D.), and P01 CA73992 and CA42014 (to S. M. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence should be addressed: Dept. of Medicine (H. Sheng) or Dept. of Surgery (R. D. Beauchamp), Vanderbilt University Medical Center, Nashville, TN, 37232. Fax: 615-343-4598; E-mail: hongmiao.sheng@ mcmail.vanderbilt.edu or daniel.beauchamp@mcmail.vanderbilt.edu.

² Dixon, D. A., Kaplan, C. D., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. (2000) J. Biol. Chem. 275, in press.

	ABBREVIATIONS

The abbreviations used are: COX-2, cyclooxygenase-2; TGF-1, transforming growth factor-1; IPTG, isopropyl-1-thio--D-galactopyranoside; RIE-iRas, rat intestinal epithelial cells that conditionally express Ha-Ras^Val12; DRB, 5,6-dichlorobenzimidazole riboside; 3'-UTR, 3'-untranslated region; ARE, AU-rich element; bp, base pair(s).

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				A. Doller, S. Gauer, E. Sobkowiak, H. Geiger, J. Pfeilschifter, and W. Eberhardt Angiotensin II Induces Renal Plasminogen Activator Inhibitor-1 and Cyclooxygenase-2 Expression Post-Transcriptionally via Activation of the mRNA-Stabilizing Factor Human-Antigen R Am. J. Pathol., April 1, 2009; 174(4): 1252 - 1263. [Abstract] [Full Text] [PDF]

				C. L. Kanies, J. J. Smith, C. Kis, C. Schmidt, S. Levy, K. S.A. Khabar, J. Morrow, N. Deane, D. A. Dixon, and R. D. Beauchamp Oncogenic Ras and Transforming Growth Factor-{beta} Synergistically Regulate AU-Rich Element-Containing mRNAs during Epithelial to Mesenchymal Transition Mol. Cancer Res., July 1, 2008; 6(7): 1124 - 1136. [Abstract] [Full Text] [PDF]

				S. Misra, L. M. Obeid, Y. A. Hannun, S. Minamisawa, F. G. Berger, R. R. Markwald, B. P. Toole, and S. Ghatak Hyaluronan Constitutively Regulates Activation of COX-2-mediated Cell Survival Activity in Intestinal Epithelial and Colon Carcinoma Cells J. Biol. Chem., May 23, 2008; 283(21): 14335 - 14344. [Abstract] [Full Text] [PDF]

				A. Doller, E.-S. Akool, A. Huwiler, R. Muller, H. H. Radeke, J. Pfeilschifter, and W. Eberhardt Posttranslational Modification of the AU-Rich Element Binding Protein HuR by Protein Kinase C{delta} Elicits Angiotensin II-Induced Stabilization and Nuclear Export of Cyclooxygenase 2 mRNA Mol. Cell. Biol., April 15, 2008; 28(8): 2608 - 2625. [Abstract] [Full Text] [PDF]

				M. T. Accioly, P. Pacheco, C. M. Maya-Monteiro, N. Carrossini, B. K. Robbs, S. S. Oliveira, C. Kaufmann, J. A. Morgado-Diaz, P. T. Bozza, and J. P.B. Viola Lipid Bodies Are Reservoirs of Cyclooxygenase-2 and Sites of Prostaglandin-E2 Synthesis in Colon Cancer Cells Cancer Res., March 15, 2008; 68(6): 1732 - 1740. [Abstract] [Full Text] [PDF]

				A. M. Johann, A. Weigert, W. Eberhardt, A.-M. Kuhn, V. Barra, A. von Knethen, J. M. Pfeilschifter, and B. Brune Apoptotic Cell-Derived Sphingosine-1-Phosphate Promotes HuR-Dependent Cyclooxygenase-2 mRNA Stabilization and Protein Expression J. Immunol., January 15, 2008; 180(2): 1239 - 1248. [Abstract] [Full Text] [PDF]

				S. D. Larson, J. Li, D. H. Chung, and B. M. Evers Molecular mechanisms contributing to glutamine-mediated intestinal cell survival Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1262 - G1271. [Abstract] [Full Text] [PDF]

				M. Liu, S.-C. Yang, S. Sharma, J. Luo, X. Cui, K. A. Peebles, M. Huang, M. Sato, R. D. Ramirez, J. W. Shay, et al. EGFR Signaling Is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 578 - 588. [Abstract] [Full Text] [PDF]

				B. Samuelsson, R. Morgenstern, and P.-J. Jakobsson Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target Pharmacol. Rev., September 1, 2007; 59(3): 207 - 224. [Abstract] [Full Text] [PDF]

				S. Eligini, S. S. Barbieri, I. Arenaz, E. Tremoli, and S. Colli Paracrine up-regulation of monocyte cyclooxygenase-2 by platelets: Role of transforming growth factor-{beta}1 Cardiovasc Res, May 1, 2007; 74(2): 270 - 278. [Abstract] [Full Text] [PDF]

				J. Shao and H. Sheng Prostaglandin E2 Induces the Expression of IL-1{alpha} in Colon Cancer Cells J. Immunol., April 1, 2007; 178(7): 4097 - 4103. [Abstract] [Full Text] [PDF]

				Y. Yu, J. Fan, Y. Hui, C. A. Rouzer, L. J. Marnett, A. J. Klein-Szanto, G. A. FitzGerald, and C. D. Funk Targeted Cyclooxygenase Gene (Ptgs) Exchange Reveals Discriminant Isoform Functionality J. Biol. Chem., January 12, 2007; 282(2): 1498 - 1506. [Abstract] [Full Text] [PDF]

				S.-R. Shiou, P. K. Datta, P. Dhawan, B. K. Law, J. M. Yingling, D. A. Dixon, and R. D. Beauchamp Smad4-dependent Regulation of Urokinase Plasminogen Activator Secretion and RNA Stability Associated with Invasiveness by Autocrine and Paracrine Transforming Growth Factor-beta J. Biol. Chem., November 10, 2006; 281(45): 33971 - 33981. [Abstract] [Full Text] [PDF]

				M. Jerkic, J. V. Rivas-Elena, J. F. Santibanez, M. Prieto, A. Rodriguez-Barbero, F. Perez-Barriocanal, M. Pericacho, M. Arevalo, C. P.H. Vary, M. Letarte, et al. Endoglin Regulates Cyclooxygenase-2 Expression and Activity Circ. Res., August 4, 2006; 99(3): 248 - 256. [Abstract] [Full Text] [PDF]

				X. Zhang, Z. Chen, M. S. Choe, Y. Lin, S.-Y. Sun, H. S. Wieand, H. J. C. Shin, A. Chen, F. R. Khuri, and D. M. Shin Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model Clin. Cancer Res., September 1, 2005; 11(17): 6261 - 6269. [Abstract] [Full Text] [PDF]

				A. Maciag, G. Sithanandam, and L. M. Anderson Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells Carcinogenesis, November 1, 2004; 25(11): 2231 - 2237. [Abstract] [Full Text] [PDF]

				H. Okano, H. Shinohara, A. Miyamoto, K. Takaori, and N. Tanigawa Concomitant Overexpression of Cyclooxygenase-2 in HER-2-Positive on Smad4-Reduced Human Gastric Carcinomas Is Associated with a Poor Patient Outcome Clin. Cancer Res., October 15, 2004; 10(20): 6938 - 6945. [Abstract] [Full Text] [PDF]

				F. Spinella, L. Rosano, V. Di Castro, M. R. Nicotra, P. G. Natali, and A. Bagnato Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells Clin. Cancer Res., July 15, 2004; 10(14): 4670 - 4679. [Abstract] [Full Text] [PDF]

				T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]

				N. R. Murray, L. Jamieson, W. Yu, J. Zhang, Y. Gokmen-Polar, D. Sier, P. Anastasiadis, Z. Gatalica, E. A. Thompson, and A. P. Fields Protein kinase C{iota} is required for Ras transformation and colon carcinogenesis in vivo J. Cell Biol., March 15, 2004; 164(6): 797 - 802. [Abstract] [Full Text] [PDF]

				D. Golijanin, J.-Y. Tan, A. Kazior, E. G. Cohen, P. Russo, G. Dalbagni, K. J. Auborn, K. Subbaramaiah, and A. J. Dannenberg Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Are Overexpressed in Squamous Cell Carcinoma of the Penis Clin. Cancer Res., February 1, 2004; 10(3): 1024 - 1031. [Abstract] [Full Text] [PDF]

				J. Shao, B. M. Evers, and H. Sheng Roles of Phosphatidylinositol 3'-Kinase and Mammalian Target of Rapamycin/p70 Ribosomal Protein S6 Kinase in K-Ras-Mediated Transformation of Intestinal Epithelial Cells Cancer Res., January 1, 2004; 64(1): 229 - 235. [Abstract] [Full Text] [PDF]

				T. G. Tessner, F. Muhale, S. Schloemann, S. M. Cohn, A. R. Morrison, and W. F. Stenson Ionizing radiation up-regulates cyclooxygenase-2 in I407 cells through p38 mitogen-activated protein kinase Carcinogenesis, January 1, 2004; 25(1): 37 - 45. [Abstract] [Full Text] [PDF]

				H Sheng, J Shao, C M Townsend jr, and B M Evers Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells Gut, October 1, 2003; 52(10): 1472 - 1478. [Abstract] [Full Text] [PDF]

				K. Subbaramaiah, T. P. Marmo, D. A. Dixon, and A. J. Dannenberg Regulation of Cyclooxgenase-2 mRNA Stability by Taxanes: EVIDENCE FOR INVOLVEMENT OF p38, MAPKAPK-2, and HuR J. Biol. Chem., September 26, 2003; 278(39): 37637 - 37647. [Abstract] [Full Text] [PDF]

				D. A. Dixon, G. C. Balch, N. Kedersha, P. Anderson, G. A. Zimmerman, R. D. Beauchamp, and S. M. Prescott Regulation of Cyclooxygenase-2 Expression by the Translational Silencer TIA-1 J. Exp. Med., August 4, 2003; 198(3): 475 - 481. [Abstract] [Full Text] [PDF]

				K. Liang, W. Jin, C. Knuefermann, M. Schmidt, G. B. Mills, K. K. Ang, L. Milas, and Z. Fan Targeting the Phosphatidylinositol 3-Kinase/Akt Pathway for Enhancing Breast Cancer Cells to Radiotherapy Mol. Cancer Ther., April 1, 2003; 2(4): 353 - 360. [Abstract] [Full Text] [PDF]

				W. Yu, N. R. Murray, C. Weems, L. Chen, H. Guo, R. Ethridge, J. D. Ceci, B. M. Evers, E. A. Thompson, and A. P. Fields Role of Cyclooxygenase 2 in Protein Kinase C beta II-mediated Colon Carcinogenesis J. Biol. Chem., March 21, 2003; 278(13): 11167 - 11174. [Abstract] [Full Text] [PDF]

				Y. Araki, S. Okamura, S. P. Hussain, M. Nagashima, P. He, M. Shiseki, K. Miura, and C. C. Harris Regulation of Cyclooxygenase-2 Expression by the Wnt and Ras Pathways Cancer Res., February 1, 2003; 63(3): 728 - 734. [Abstract] [Full Text] [PDF]

				T. G. Tessner, F. Muhale, S. Schloemann, S. M. Cohn, A. Morrison, and W. F. Stenson Basic fibroblast growth factor upregulates cyclooxygenase-2 in I407 cells through p38 MAP kinase Am J Physiol Gastrointest Liver Physiol, February 1, 2003; 284(2): G269 - G279. [Abstract] [Full Text] [PDF]

				A. Pedram, M. Razandi, M. Aitkenhead, C. C. W. Hughes, and E. R. Levin Integration of the Non-genomic and Genomic Actions of Estrogen. MEMBRANE-INITIATED SIGNALING BY STEROID TO TRANSCRIPTION AND CELL BIOLOGY J. Biol. Chem., December 20, 2002; 277(52): 50768 - 50775. [Abstract] [Full Text] [PDF]

				Y.-S. Guo, J.-Z. Cheng, G.-F. Jin, J. S. Gutkind, M. R. Hellmich, and C. M. Townsend Jr. Gastrin Stimulates Cyclooxygenase-2 Expression in Intestinal Epithelial Cells through Multiple Signaling Pathways. EVIDENCE FOR INVOLVEMENT OF ERK5 KINASE AND TRANSACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR J. Biol. Chem., December 6, 2002; 277(50): 48755 - 48763. [Abstract] [Full Text] [PDF]

				J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862. [Abstract] [Full Text] [PDF]

				M. C. Specht, O. N. Tucker, M. Hocever, D. Gonzalez, L. Teng, and T. J. Fahey III Cyclooxygenase-2 Expression in Thyroid Nodules J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 358 - 363. [Abstract] [Full Text] [PDF]

				K. Yoshimatsu, D. Golijanin, P. B. Paty, R. A. Soslow, P.-J. Jakobsson, R. A. DeLellis, K. Subbaramaiah, and A. J. Dannenberg Inducible Microsomal Prostaglandin E Synthase Is Overexpressed in Colorectal Adenomas and Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3971 - 3976. [Abstract] [Full Text] [PDF]

				J. Fujita, J. R. Mestre, J. B. Zeldis, K. Subbaramaiah, and A. J. Dannenberg Thalidomide and Its Analogues Inhibit Lipopolysaccharide-mediated Induction of Cyclooxygenase-2 Clin. Cancer Res., November 1, 2001; 7(11): 3349 - 3355. [Abstract] [Full Text] [PDF]

				G. A. FitzGerald and C. Patrono The Coxibs, Selective Inhibitors of Cyclooxygenase-2 N. Engl. J. Med., August 9, 2001; 345(6): 433 - 442. [Full Text] [PDF]

				I. A. Mardini and G. A. FitzGerald Selective Inhibitors of Cyclooxygenase-2: A Growing Class of Anti-Inflammatory Drugs Mol. Interv., April 1, 2001; 1(1): 30 - 38. [Abstract] [Full Text]

				L. B. Nabors, G. Y. Gillespie, L. Harkins, and P. H. King HuR, a RNA Stability Factor, Is Expressed in Malignant Brain Tumors and Binds to Adenine- and Uridine-rich Elements within the 3' Untranslated Regions of Cytokine and Angiogenic Factor mRNAs Cancer Res., March 1, 2001; 61(5): 2154 - 2161. [Abstract] [Full Text]

				H. Sheng, J. Shao, and R. N. DuBois K-Ras-mediated Increase in Cyclooxygenase 2 mRNA Stability Involves Activation of the Protein Kinase B Cancer Res., March 1, 2001; 61(6): 2670 - 2675. [Abstract] [Full Text]

				K. Xu, A. M. Robida, and T. J. Murphy Immediate-early MEK-1-dependent Stabilization of Rat Smooth Muscle Cell Cyclooxygenase-2 mRNA by Galpha q-coupled Receptor Signaling J. Biol. Chem., July 21, 2000; 275(30): 23012 - 23019. [Abstract] [Full Text] [PDF]

				J. Shao, H. Sheng, H. Inoue, J. D. Morrow, and R. N. DuBois Regulation of Constitutive Cyclooxygenase-2 Expression in Colon Carcinoma Cells J. Biol. Chem., October 20, 2000; 275(43): 33951 - 33956. [Abstract] [Full Text] [PDF]

				B.-C. Jang, T. Sanchez, H.-J. Schaefers, O. C. Trifan, C. H. Liu, C. Creminon, C.-K. Huang, and T. Hla Serum Withdrawal-induced Post-transcriptional Stabilization of Cyclooxygenase-2 mRNA in MDA-MB-231 Mammary Carcinoma Cells Requires the Activity of the p38 Stress-activated Protein Kinase J. Biol. Chem., December 8, 2000; 275(50): 39507 - 39515. [Abstract] [Full Text] [PDF]

				J. R. Mestre, P. J. Mackrell, D. E. Rivadeneira, P. P. Stapleton, T. Tanabe, and J. M. Daly Redundancy in the Signaling Pathways and Promoter Elements Regulating Cyclooxygenase-2 Gene Expression in Endotoxin-treated Macrophage/Monocytic Cells J. Biol. Chem., February 2, 2001; 276(6): 3977 - 3982. [Abstract] [Full Text] [PDF]

				S. J. Cok and A. R. Morrison The 3'-Untranslated Region of Murine Cyclooxygenase-2 Contains Multiple Regulatory Elements That Alter Message Stability and Translational Efficiency J. Biol. Chem., June 15, 2001; 276(25): 23179 - 23185. [Abstract] [Full Text] [PDF]

				H. Sheng, J. Shao, and R. N. DuBois Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells J. Biol. Chem., April 20, 2001; 276(17): 14498 - 14504. [Abstract] [Full Text] [PDF]

				D. Saha, P. K. Datta, and R. D. Beauchamp Oncogenic Ras Represses Transforming Growth Factor-beta /Smad Signaling by Degrading Tumor Suppressor Smad4 J. Biol. Chem., July 27, 2001; 276(31): 29531 - 29537. [Abstract] [Full Text] [PDF]

				Y.-S. Guo, M. R. Hellmich, X. D. Wen, and C. M. Townsend Jr. Activator Protein-1 Transcription Factor Mediates Bombesin-stimulated Cyclooxygenase-2 Expression in Intestinal Epithelial Cells J. Biol. Chem., June 15, 2001; 276(25): 22941 - 22947. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sheng, H. Articles by Beauchamp, R. D. Search for Related Content PubMed PubMed Citation Articles by Sheng, H. Articles by Beauchamp, R. D. Social Bookmarking                      What's this?